159 related articles for article (PubMed ID: 15195129)
1. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.
Dostalova S; Polanska H; Svobodova M; Balvan J; Krystofova O; Haddad Y; Krizkova S; Masarik M; Eckschlager T; Stiborova M; Heger Z; Adam V
Sci Rep; 2018 Jun; 8(1):8867. PubMed ID: 29891921
[TBL] [Abstract][Full Text] [Related]
4. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.
Carter T; Sterling-Levis K; Ow K; Doughty L; Hattarki M; Shapira D; Hewish D; Kortt AA; Russell PJ
Cancer Immunol Immunother; 2004 Jun; 53(6):533-42. PubMed ID: 14722669
[TBL] [Abstract][Full Text] [Related]
5. Design and Evaluation of
Lankoff A; Czerwińska M; Walczak R; Karczmarczyk U; Tomczyk K; Brzóska K; Fracasso G; Garnuszek P; Mikołajczak R; Kruszewski M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071854
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies.
Russell PJ; Hewish D; Carter T; Sterling-Levis K; Ow K; Hattarki M; Doughty L; Guthrie R; Shapira D; Molloy PL; Werkmeister JA; Kortt AA
Cancer Immunol Immunother; 2004 May; 53(5):411-21. PubMed ID: 14722668
[TBL] [Abstract][Full Text] [Related]
7. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
[TBL] [Abstract][Full Text] [Related]
8. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
9. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
Derks YHW; Schilham MGM; Rijpkema M; Smeets EMM; Amatdjais-Groenen HIV; Kip A; van Lith SAM; van de Kamp J; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Heskamp S; Lütje S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2872-2884. PubMed ID: 37060367
[TBL] [Abstract][Full Text] [Related]
10. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Gregor PD; Wolchok JD; Turaga V; Latouche JB; Sadelain M; Bacich D; Heston WD; Houghton AN; Scher HI
Int J Cancer; 2005 Sep; 116(3):415-21. PubMed ID: 15800947
[TBL] [Abstract][Full Text] [Related]
11. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer.
Dhull A; Wei J; Pulukuri AJ; Rani A; Sharma R; Mesbahi N; Yoon H; Savoy EA; Xaivong Vi S; Goody KJ; Berkman CE; Wu BJ; Sharma A
Nanoscale; 2024 Mar; 16(11):5634-5652. PubMed ID: 38440933
[TBL] [Abstract][Full Text] [Related]
12. Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.
Sakamoto S; Inoue H; Kaneko MK; Ogasawara S; Kajikawa M; Urano S; Ohba SI; Kato Y; Kawada M
Cancer Sci; 2019 Nov; 110(11):3595-3602. PubMed ID: 31512325
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.
Webb KS; Ware JL; Parks SF; Briner WH; Paulson DF
Cancer Immunol Immunother; 1983; 14(3):155-66. PubMed ID: 6188529
[TBL] [Abstract][Full Text] [Related]
14. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.
Russell PJ; Ow KT; Tam PN; Juarez J; Kingsley EA; Qu CF; Li Y; Cozzi PJ; Martiniello-Wilks R
Cancer Immunol Immunother; 2004 Nov; 53(11):995-1004. PubMed ID: 15449043
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen A
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
Weber JS; Vogelzang NJ; Ernstoff MS; Goodman OB; Cranmer LD; Marshall JL; Miles S; Rosario D; Diamond DC; Qiu Z; Obrocea M; Bot A
J Immunother; 2011 Sep; 34(7):556-67. PubMed ID: 21760528
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner AA
bioRxiv; 2023 Sep; ():. PubMed ID: 37745586
[TBL] [Abstract][Full Text] [Related]
19. Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.
Czerwińska M; Bilewicz A; Kruszewski M; Wegierek-Ciuk A; Lankoff A
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290196
[TBL] [Abstract][Full Text] [Related]
20. Linalool inhibits 22Rv1 prostate cancer cell proliferation and induces apoptosis.
Zhao Y; Cheng X; Wang G; Liao Y; Qing C
Oncol Lett; 2020 Dec; 20(6):289. PubMed ID: 33029205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
